EUCTR2007-003723-21-SE进行中（未招募）不适用
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiency
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 525
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Age in the range of 18-85 years inclusive at visit 1
- •2.Patients with T2DM either untreated (defined as not taking anti-diabetic therapy for at least 8 weeks prior to visit 1) or treated with anti-diabetic therapy defined as sulfonylurea, AGIs, TZDs, insulin, and metiglinides as monotherapy or combination therapy for at least 8 weeks prior to visit 1
- •3.Patients treated with anti-diabetic therapy must be on a stable dose for the past 4 weeks prior to visit 1 (stable insulin therapy is defined as ± 20% of total daily units)
- •4.GFR estimated by the Cockcroft-Gault formula of = 30 and < 50 mL/min at visit 1
- •5.HbA1c of = 6.5 and = 10 % at visit 1
- •6.Body weight < 120 kg and body mass index (BMI) 18-42 kg/m2 at visit 1
- •7.Male, non-fertile female or female of childbearing potential using a medically approved birth control method by the country health authorities that may include:
- •A non-fertile female is defined as: post menopausal (12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone (FSH) levels > 40 mLU/m); 6 weeks post bilateral oophorectomy with or without hysterectomy; post hysterectomy; or sterilized by tubal ligation
- •A female of childbearing potential is defined as any woman physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means
- •Medically approved birth control methods may include: hormonal contraceptives, intrauterine contraceptive device (IUD), and double-barrier contraception. Acceptable methods of contraception may include total abstinence at the discretion of the investigator in cases where the age, career, lifestyle, or sexual orientation of the subject ensures compliance. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
- •Reliable contraception should be maintained throughout the study
- •8.Agreement to continue their current diet/exercise regimen and sulfonylurea, AGI, TZD, insulin, or metiglinide therapy throughout the duration of the study or to remain untreated if patient is not taking anti-diabetic therapy, unless otherwise instructed by the trial’s physician
- •9.Written informed consent to participate in the study and ability to comply with all study requirements
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.FPG = 270 mg/dL (=15 mmol/L)
- •2.Pregnant or lactating female
- •3.A history of:
- •Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, e.g. Cushing’s syndrome and acromegaly
- •Acute metabolic diabetic complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months
- •4.Patients that have been enrolled in a vildagliptin clinical trial or other DPP-4 inhibitor, GLP-1 mimetics (e.g. exenatide), GLP-1 analogues (e.g. liraglutide) studies within six months prior to visit 1
- •5.History of renal transplant at any time in the past
- •6.Acute infections which may affect blood glucose control within 4 weeks prior to visit 1 and other concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study
- •7.Any pre-existing lower extremity diabetic skin ulcer
- •8.Patients taking TZDs with established peripheral edema
- •9.Congestive heart failure (New York Heart Association (NYHA) class III-IV)
- •10.Any of the following within the past 6 months:
- •myocardial infarction (MI) (if the visit 1 ECG reveals patterns consistent with a MI and the date of the event cannot be determined, then the patient can enter the clinical trial at the discretion of the investigator and/or local medical monitor);
- •unstable angina
- •coronary artery bypass surgery or percutaneous coronary intervention;
- •11.Any of the following ECG abnormalities:
- •Torsades de pointes, sustained and clinically relevant ventricular tachycardia or ventricular fibrillation
- •second degree AV block (Mobitz 1 and 2)
- •third degree AV block
- •prolonged QTc (> 500 ms)
- •12.Malignancy including leukemia and lymphoma (not including basal cell skin cancer) within the last 5 years
- •13.Liver disease such as cirrhosis or chronic active hepatitis B and C
- •15.Concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study
- •16.Any of the following concomitant medications:
- •any anti-diabetic therapy other than sulfonylureas, AGIs, TZDs, insulin, and metiglinides within 8 weeks prior to visit 1
- •chronic oral or parenteral corticosteroid treatment (> 7 consecutive days of treatment) within 8 weeks prior to visit 1
- •treatment with class Ia, Ib and Ic or III anti-arrhythmics
- •treatment with growth hormone or similar drugs
- •treatment with probenecid
- •treatment with any medication that is contraindicated in the renal impaired population (GFR < 50 mL/min: as calculated by Cockcroft-Gault formula)
- •treatment with any medication that is contraindicated in the use with sulfonylureas, AGIs, TZDs, insulin, and metiglinides
- •use of other investigational drugs within 30 days or 5 half-lives of the drug at visit 1, which ever is longer, unless local health authority guidelines mandate a longer period
- •treatment with any drug with a known and frequent toxicity to a major organ system within the past 3 months (i.e. cytostatic drugs)
- •17.Any of the following significant laboratory abnormalities:
- •Clinically significant thyroid stimulating hormone (TSH) outside of normal range at visit 1
- •Clinically significant laboratory abnormalities at the opinion of the investigator
- •Patients with a serum albumin < 3.0 g/dL at visit 1
- •Patients with a hemoglobin concentration < 9 g/dL at visit 1
- •Elevated fasting triglycerides > 500 mg/dL at visit 1, confirmed by a repeat measure within 3 working days
- •Alanine aminotransferase (ALT) and/or
研究者
相似试验
进行中（未招募）
不适用
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiencyEUCTR2007-003723-21-DEovartis Pharma Services AG525
进行中（未招募）
不适用
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus placebo in patients with type 2 diabetes and moderate renal insufficiency - NDEUCTR2007-003723-21-ITOVARTIS FARMA300
进行中（未招募）
不适用
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus placebo in patients with type 2 diabetes and moderate renal insufficiencyDiabetes Type 2MedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2007-003723-21-FIovartis Pharma Services AG300
进行中（未招募）
不适用
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus placebo in patients with type 2 diabetes and moderate renal insufficiencyEUCTR2007-003723-21-FRovartis Pharma Services AG300
已完成
3 期
Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal InsufficiencyCTRI/2009/091/000238ovartis Healthcare Private Limited300